In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Arrowhead Research licenses Shire rights to homing peptide platform

Executive Summary

Rare disease drug developer Shire PLC has received a worldwide license to use Arrowhead Research Corp.’s (has compounds in development for cancer and metabolic and infectious diseases) human-derived homing peptide platform to develop and commercialize targeted peptide-drug conjugates (PDCs) with its own therapeutic payloads.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies